Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 13, Issue 5, Pages 778-785Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2013.05.006
Keywords
-
Categories
Funding
- Edmond J. Safra Bioinformatics Center at Tel-Aviv University
- Azrieli Foundation
- Whitaker Foundation
- Dan David Foundation
- Israeli Science Foundation (ISF)
- Microme project (EU FP7)
- Israeli Centers of Research Excellence, Gene Regulation in Complex Human Disease Center [41/11]
Ask authors/readers for more resources
Costs for drug development have soared, exposing a clear need for new R&D strategies. Systems biology has meanwhile emerged as an attractive vehicle for integrating omics data and other post-genomic technologies into the drug pipeline. One of the emerging areas of computational systems biology is constraint-based modeling (CBM), which uses genome-scale metabolic models (GSMMs) as platforms for integrating and interpreting diverse omics datasets. Here we review current uses of GSMMs in drug discovery, focusing on prediction of novel drug targets and promising lead compounds. We then expand our discussion to prediction of toxicity and selectivity of potential drug targets. We discuss successes as well as limitations of GSMMs in these areas. Finally, we suggest new ways in which GSMMs may contribute to drug discovery, offering our vision of how GSMMs may re-model the drug pipeline in years to come.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available